SOPHiA GENETICS CLO sells 6,168 shares at $7.63

Chief Legal Officer Daan Van Well sold 6,168 SOPH shares under a Rule 10b5-1 trading plan, retaining 338,884 shares.

Available on EDGAR 09/14/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) reported that its Chief Legal Officer, Daan Van Well, sold 6,168 ordinary shares on September 11, 2026 in an open-market or private transaction. The weighted average sale price was about $7.63 per share, with individual trades between $7.55 and $7.85. After this sale, the officer directly held 338,884 ordinary shares. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.

Insider Trade Summary 10b5-1

Net Seller: 6,168 shares

Net Sell 1 txn

Insider Van Well Daan

Role Chief Legal Officer

Sold 6,168 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	6,168	$7.6344	$47K

Holdings After Transaction: Ordinary Shares — 338,884 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.55 to $7.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 6,168 shares Weighted average sale price: $7.63 per share Sale price range: $7.55–$7.85 per share +2 more

5 metrics

Shares sold 6,168 shares Ordinary shares sold by the Chief Legal Officer on September 11, 2026

Weighted average sale price $7.63 per share Average price for the 6,168 shares sold on September 11, 2026

Sale price range $7.55–$7.85 per share Price range of individual trades included in the reported sale

Shares held after transaction 338,884 shares Direct ownership of ordinary shares by the Chief Legal Officer after the sale

Number of reported insider sales 1 transaction Non-derivative sale reported in this Form 4

Key Terms

Rule 10b5-1(c), weighted average price, ordinary shares

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

ordinary shares financial

"The shares were sold in multiple transactions at prices ranging from $7.55 to $7.85, inclusive."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPH report for Chief Legal Officer Daan Van Well?

SOPHiA GENETICS SA reported that Chief Legal Officer Daan Van Well sold 6,168 ordinary shares on September 11, 2026 in an open-market or private transaction at a weighted average price of $7.63 per share.

How many SOPH shares does Daan Van Well hold after the reported sale?

After the reported transaction, Chief Legal Officer Daan Van Well directly held 338,884 ordinary shares of SOPHiA GENETICS SA.

What was the price range for the SOPH shares sold by Daan Van Well?

The filing states that the 6,168 shares sold by Chief Legal Officer Daan Van Well on September 11, 2026 were executed at prices ranging from $7.55 to $7.85 per share, with a weighted average price of $7.63 per share.

Was the SOPH insider sale by Daan Van Well under a Rule 10b5-1 plan?

Yes. The transaction for 6,168 ordinary shares by Chief Legal Officer Daan Van Well was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), as disclosed in the filing footnotes.

How many SOPH insider share sales were reported in this Form 4?

The Form 4 for SOPHiA GENETICS SA reports one non-derivative transaction: a sale of 6,168 ordinary shares by Chief Legal Officer Daan Van Well on September 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Well Daan

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/11/2026		S		6,168(1)	D	$7.6344(2)	338,884	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.55 to $7.85, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)